Process development innovations to improve gene therapy manufacturing
Sponsor
Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
As viral vector-based gene therapies move toward indications with larger patient populations, the pressure to improve manufacturing efficiency is rising. To support efficient manufacturing, therapeutic developers must begin by putting a robust process development (PD) plan in place. The industry has been working towards a robust PD plan using innovation, such as, templated processes to improve yield while reducing costs of goods sold (GOGS) and time-to-clinic. While templates will help, there will always be a need for PD to optimize the upstream/transfection, as well as downstream due to differences in the gene of interest (GOI). In this panel style webinar, our experts will discuss the PD innovations that our teams are working on to improve manufacturability, robustness of analytical testing, and scale-down models to meet the needs of large-scale manufacturing.
- Process Development is a critical service to support robust manufacturing of viral vector-based therapies.
- Without a proper PD plan in place, outcomes include manufacturing failures, product impurities, low titer/yield, increased costs to developers and more time spent on product release.
- Continued innovations in PD are necessary to industrialize the industry and support successful large-scale manufacturing.
- Our design of experiment (DOE) studies have optimized upstream and downstream processes.
- How we can help map out your process and assess manufacturability
SPEAKERS
You might also like
Revolutionary innovations are underway to industrialize cell and gene therapies
Revolutionizing upstream gene therapy manufacturing with nanofiber microcarriers
From development to manufacturing: ensuring quality and functionality in gene therapy
How to use AI and machine learning in cell therapy process development
